The Patent Finder

Terms ending in 2031

Abraxis Bioscience, LLC

Every in-force patent on Abraxis Bioscience, LLC's record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,370,494Methods for Treating Hepatocellular Carcinoma
In force
 · High confidence
Abraxis Bioscience, LLCIn forceHigh confidence
US 9,820,949Methods of Treatment of Pancreatic Cancer
In force
 · Medium confidence
Abraxis Bioscience, LLCIn forceMedium confidence
US 10,660,965Methods of Enhancing Drug Delivery and Effectiveness of Therapeutic Agents
In force
 · High confidence
Abraxis Bioscience, LLPIn forceHigh confidence
US 9,399,071Methods of Treatment of Pancreatic Cancer
In force
 · High confidence
Abraxis Bioscience, LLCIn forceHigh confidence
US 9,399,072Methods of Treatment of Pancreatic Cancer
In force
 · High confidence
Abraxis Bioscience, LLCIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited